N/A
N=35
Downstream Molecular Signals of P2Y12 Receptors in Hyporeactive Patients Under Clopidogrel Treatment A Possible Mechanism of HOTPR(High On-Treatment Platelet Reactivity)
Stable Angina
Bottom Line
View on ClinicalTrials.gov: NCT03190005 ↗Enrolled (actual)
35
Serious AEs
0.0%
Results posted
Nov 2019
Primary outcome: Primary: PRU(Platelet Rreactivity Unit) 24 Hours After DAPT(Dual AntiPlatelet Therapy) Western Blot After Medication — 148; 289; 79; 132 PRU(Platelet Rreactivity Unit)
Study Design & Population
- Study type
- Observational
- Phase
- N/A
- Interventions
- clopidogrel (Drug); Placebos (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Taipei City Hospital
- Primary completion
- Nov 2017
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY PRU(Platelet Rreactivity Unit) 24 Hours After DAPT(Dual AntiPlatelet Therapy) Western Blot After Medication |
148; 289; 79; 132; 81; 62 | — |
Summary
The investigators designed the following experiment to observe the pattern of administration in vitro, which can be completely excluded liver enzyme cytochrome P450 metabolism under the influence and observe the relevant P2Y12 receptor downstream signal changes, hope in the above experiments, that the human body directly for the difference between the existence of drug reactions exist.
Eligibility Criteria
Inclusion Criteria
- DAPT(Dual antiplatelet therapy) after regular stent implantation.
Exclusion Criteria
- allergy to DAPT(Dual antiplatelet therapy). major bleeding intolerance to DAPT(Dual antiplatelet therapy).
Data sourced from ClinicalTrials.gov (NCT03190005). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.